Connect with us

Technology

Dr. Lynn Welch and S&G Labs Launch Inaugural S&G Scholarship for Veterans, Pioneering Educational Support for Those Who Served

Published

on

ENGLEWOOD, Colo., July 15, 2026 /PRNewswire/ — S&G Labs, founded by Dr. Lynn Welch, today announced the launch of the S&G Scholarship for Veterans, a new initiative designed to support undergraduate student veterans as they pursue higher education and prepare for meaningful careers. The scholarship reflects the organization’s deep commitment to service, opportunity, and community impact, honoring those who have served the nation with dedication and distinction.

Dr. Lynn Welch, a physician who has cared for patients on Hawaii’s Big Island since 2008, established S&G Labs to address the growing need for precise medication monitoring and expert laboratory services.

The S&G Labs Scholarship for Veterans was created to honor the service and sacrifice of military veterans who are pursuing higher education.

Eligibility and Application Requirements

To be considered for the S&G Scholarship for Veterans, applicants must meet the following criteria:

Be currently enrolled as an undergraduate student at an accredited college or university in the United States.Be a veteran of the United States Armed Forces.Be in good academic standing.Submit a complete application before the scholarship deadline.Submit an original essay between 500 and 800 words responding to the following prompt:

“Military service often shapes leadership abilities, resilience, and a sense of purpose. Describe how your experience as a veteran has influenced your educational journey and future career goals. Discuss the lessons you learned through service, how those lessons have impacted your approach to challenges, and how you plan to use your education to make a meaningful contribution to your community, profession, or society.”

Submission Process and Deadlines

Eligible applicants should submit the following materials via email to apply@sandgscholarship.com:

Full NameContact Information (Email Address and Phone Number)Name of Current College or UniversityProof of Undergraduate EnrollmentProof of Veteran StatusOriginal Essay (500–800 words) responding to the scholarship prompt

The deadline to apply for the scholarship is March 15, 2027. The winner will be announced on April 15, 2027.

About S&G Labs

S&G Labs is a leader in advanced medication monitoring and drug detection services, providing clinicians with innovative tools that support personalized patient care.

View original content:https://www.prnewswire.com/news-releases/dr-lynn-welch-and-sg-labs-launch-inaugural-sg-scholarship-for-veterans-pioneering-educational-support-for-those-who-served-302826811.html

SOURCE S&G Scholarship for Veterans

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

Published

on

By

WASHINGTON, July 15, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention of vomiting induced by motion in 47 years, will sponsor the No. 47 entry in the NTT IndyCar Series with Rahal Letterman Lanigan Racing.

The partnership aligns NEREUS’™ breakthrough innovation in motion relief with the high-speed world of IndyCar racing, where focus and stability are essential.

This sponsorship marks a symbolic milestone: 47 years since the last new motion sickness treatment was introduced in the United States. NEREUS™ represents a modern advancement as a selective NK-1 receptor antagonist designed to prevent vomiting induced by motion, offering a new option for millions who experience motion sickness during travel.

“Partnering with the No. 47 car perfectly captures this historic moment and our shared commitment to performance under challenging conditions,” said Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda. 

The NEREUS™-branded No. 47 IndyCar will feature prominent sponsorship visibility across select NTT IndyCar Series events in 2026.

About NEREUS™ (tradipitant)

NEREUS™ is an oral NK-1 receptor antagonist FDA-approved for the prevention of vomiting induced by motion in adults. It is the first new pharmacologic treatment approved for this indication in over four decades.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

About Rahal Letterman Lanigan Racing

Rahal Letterman Lanigan Racing is a championship-winning team competing in the NTT IndyCar Series.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com 

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com

Follow us on X @vandapharma

View original content to download multimedia:https://www.prnewswire.com/news-releases/nereus-powers-forward-sponsors-no-47-indycar-entry-celebrating-47-years-since-last-new-us-motion-sickness-treatment-302826721.html

SOURCE Vanda Pharmaceuticals Inc.

Continue Reading

Technology

VIAVI Announces Date for Fiscal Fourth Quarter and Fiscal Year 2026 Financial Results

Published

on

By

CHANDLER, Ariz., July 15, 2026 /PRNewswire/ — Viavi Solutions Inc. (VIAVI) (NASDAQ: VIAV) will announce its fiscal fourth quarter and fiscal year 2026 financial results for the period ended June 27, 2026, on Wednesday, August 5, 2026, after the close of market.

The Company will host an earnings call at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast of the call and the replay will be available on the VIAVI website at https://investor.viavisolutions.com. The quarterly earnings press release, supplementary slides and historical financial tables will be posted under the “Quarterly Results” section.

To participate via telephone:

Toll-Free Dial-In Number:

1 (833) 461-5787

Toll Dial-In Number:

1 (585) 542-9983

Conference ID:

687 725 628

About VIAVI Solutions
VIAVI (NASDAQ: VIAV) is a global leader in test and measurement and optical technologies. Our test, monitoring, assurance, and resilient position, navigation and timing solutions enable and secure critical infrastructure ranging from data center ecosystems and communication networks to military, aerospace, railway and first responder communications. In addition, we develop and advance technologies used in high-volume optical applications across anti-counterfeiting, consumer electronics, aerospace, industrial and automotive end markets.

Learn more about VIAVI at www.viavisolutions.com. Follow us on VIAVI PerspectivesLinkedIn and YouTube.

Investors Contact:
Vibhuti Nayar, 408-404-6305; investor.relations@viavisolutions.com
Press Contact:
Amit Malhotra, 202-341-8624; amit.malhotra@viavisolutions.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/viavi-announces-date-for-fiscal-fourth-quarter-and-fiscal-year-2026-financial-results-302822275.html

SOURCE VIAVI Financials

Continue Reading

Technology

The American Council of the Blind to Distribute Ray-Ban Meta AI Glasses to Blind Veterans in St. Louis on July 27

Published

on

By

ALEXANDRIA, Va., July 15, 2026 /PRNewswire/ — The American Council of the Blind is proud to partner with Meta and the Blinded Veterans Association (BVA) to distribute Ray-Ban Meta AI glasses to eligible veterans who are blind during the upcoming 2026 ACB Conference and Convention in St. Louis.

The distribution will take place on Monday, July 27, from 1 to 5 p.m. CT at the Hyatt St. Louis at The Arch in downtown St. Louis. Eligible veterans can receive Ray-Ban Meta AI glasses at no cost while supplies last and a complimentary day pass to the ACB convention for July 27.

The initiative is part of Meta’s commitment to donate Ray-Ban Meta AI glasses to 130,000 blinded veterans worldwide, expanding access to technology that can support greater independence, access to information, and everyday tasks. As a distribution partner, ACB will also provide access to training resources for veterans receiving Meta glasses.

“Supporting veterans who are blind or have low vision has long been an important part of ACB’s mission,” said ACB Executive Director Scott Thornhill. “We are honored to partner with Meta and BVA to help connect veterans with innovative technology that can make a meaningful difference in their daily lives.”

Ray-Ban Meta AI glasses combine a lightweight, hands-free design with built-in artificial intelligence to help users complete everyday tasks more independently. Wearers can ask the glasses to describe their surroundings, read printed text, identify objects, and capture photos or videos.

To receive a pair of Ray-Ban Meta AI glasses at the July 27 distribution event, individuals must provide proof of military service, acknowledge legal blindness, and own a compatible smart phone.

A day pass to the ACB Conference and Convention with access to the Exhibit Hall will be available for recipients.

For more details about the Ray-Ban Meta AI glasses distribution, visit https://www.acb.org/glasses.

About the American Council of the Blind

The American Council of the Blind is a national member-driven consumer organization representing Americans who are blind or have low vision. With 65 affiliates, ACB strives to increase independence, security, equality of opportunity, and to improve the quality of life for all people who are blind or have low vision. For more information, visit https://www.acb.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-american-council-of-the-blind-to-distribute-ray-ban-meta-ai-glasses-to-blind-veterans-in-st-louis-on-july-27-302826844.html

SOURCE American Council of the Blind

Continue Reading

Trending